J&J's Nipocalimab Shows Promise Against gMG

J&J's Nipocalimab Shows Promise Against gMG

Matteo Rossi
2 min read

Johnson & Johnson's Nipocalimab Shows Promising Phase III Results in Treating Myasthenia Gravis

Johnson & Johnson (J&J) has unveiled encouraging Phase III outcomes for nipocalimab, an antibody that has demonstrated significant improvement in the symptoms of generalized myasthenia gravis (gMG). The VIVACITY trial, which encompassed 153 adults with gMG, exhibited a substantial decrease in daily activity scores in comparison to the placebo. Additionally, nipocalimab achieved positive results in enhancing muscle strength and function, meeting secondary endpoints. Acquired through J&J's $6.5 billion acquisition of Momenta Pharmaceuticals in 2020, the therapy operates by inhibiting a receptor responsible for elevating levels of detrimental IgG antibodies. J&J intends to present these findings to regulatory bodies later this year.

Nipocalimab's primary rival, Argenx's Vyvgart, has already obtained approval for gMG treatment and is anticipated to yield greater sales by 2030. The safety profile of the trial manifested similarities between the groups administered with nipocalimab and the placebo, with comparable rates of adverse events. Moreover, nipocalimab has displayed promise in trials targeting other immune disorders such as Sjogren’s disease, haemolytic disease of the fetus and newborn (HDFN), and rheumatoid arthritis.

Key Takeaways

  • Johnson & Johnson's nipocalimab demonstrates positive Phase III results in addressing myasthenia gravis.
  • Nipocalimab targets the reduction of IgG antibodies, obtained through the $6.5 billion deal with Momenta Pharmaceuticals.
  • J&J plans to submit Phase III data to regulatory agencies this year.
  • Argenx's Vyvgart achieved $1.2 billion in sales in 2023.
  • GlobalData projects Vyvgart sales to reach $6.5 billion by 2030, in contrast to $1.8 billion for nipocalimab.


Johnson & Johnson's triumphant Phase III trial for nipocalimab has the potential to disrupt the myasthenia gravis market, directly challenging the prevailing dominance of Argenx's Vyvgart. J&J's substantial acquisition of Momenta Pharmaceuticals for $6.5 billion in 2020 serves as a pivotal foundation for this strategic advancement. In the short term, J&J's submissions to regulatory authorities may elevate stock value, while in the long run, the expansion of nipocalimab into other immune disorders could diversify revenue sources. Conversely, Argenx is confronted with augmented competition that could potentially diminish the projected $6.5 billion sales of Vyvgart by 2030. The financial stability and research and development investments of both companies will shape the trajectory of this evolving market landscape.

Did You Know?

  • Generalized Myasthenia Gravis (gMG):
    • This represents a chronic autoimmune neuromuscular disorder characterized by varying degrees of skeletal muscle weakness.
    • The condition ensues when the communication between nerve cells and muscles is disrupted, typically due to the body's immune system mistakenly attacking these connections.
  • Nipocalimab:
    • This is an investigational antibody engineered by Johnson & Johnson, acquired through the $6.5 billion acquisition of Momenta Pharmaceuticals in 2020.
    • It functions by obstructing the FcRn receptor, which is involved in the recycling of IgG antibodies, thereby diminishing their detrimental levels in the body.
  • Vyvgart (Efgartigimod) by Argenx:
    • This stands as a pioneering therapeutic antibody fragment designed to mitigate disease-causing IgG antibodies.
    • It has been sanctioned for gMG treatment and is expected to pose substantial competition to nipocalimab in the market.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings